Literature DB >> 34023065

ASGE guideline on the management of cholangitis.

James L Buxbaum1, Carlos Buitrago1, Alice Lee1, Badih Joseph Elmunzer2, Ahsun Riaz3, Eugene P Ceppa4, Mohammed Al-Haddad5, Stuart K Amateau6, Audrey H Calderwood7, Douglas S Fishman8, Larissa L Fujii-Lau9, Laith H Jamil10, Terry L Jue11, Richard S Kwon12, Joanna K Law13, Jeffrey K Lee14, Mariam Naveed15, Swati Pawa16, Mandeep S Sawhney17, Hannah Schilperoort1, Andrew C Storm18, Nirav C Thosani19, Bashar J Qumseya20, Sachin Wani21.   

Abstract

Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for management of cholangitis. This document addresses the modality of drainage (endoscopic vs percutaneous), timing of intervention (<48 hours vs >48 hours), and extent of initial intervention (comprehensive therapy vs decompression alone). Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.
Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34023065     DOI: 10.1016/j.gie.2020.12.032

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  1 in total

Review 1.  Optimal timing of biliary drainage based on the severity of acute cholangitis: A single-center retrospective cohort study.

Authors:  Zhao-Qing Lu; Han-Yu Zhang; Chen-Fen Su; Yue-Yan Xing; Guo-Xing Wang; Chun-Sheng Li
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.